SYSTEMATIC REVIEW article

Front. Psychiatry, 16 July 2025

Sec. Sleep Disorders

Volume 16 - 2025 | https://doi.org/10.3389/fpsyt.2025.1606743

Poor sleep quality among patients with Parkinson’s disease: a meta-analysis and systematic review

  • 1. Macao Observatory for Social Development, University of Saint Joseph, Macao, Macao SAR, China

  • 2. Unit of Psychiatry, Department of Public Health and Medicinal Administration, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao, Macao SAR, China

  • 3. Centre for Cognitive and Brain Sciences, University of Macau, Macao, Macao SAR, China

  • 4. Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China

  • 5. Section of Psychiatry, University of Notre Dame Australia, Fremantle, WA, Australia

  • 6. Division of Psychiatry, School of Medicine, University of Western Australia, Perth, WA, Australia

  • 7. School of Public Health, Southeast University, Nanjing, China

  • 8. School of Nursing, Hong Kong Polytechnic University, Hong Kong, Hong Kong SAR, China

  • 9. Department of Psychiatry, The Melbourne Clinic and St Vincent’s Hospital, University of Melbourne, Richmond, VIC, Australia

  • 10. Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China

Article metrics

View details

2,9k

Views

757

Downloads

Abstract

Objective:

Poor sleep quality is common among patients with Parkinson’s disease (PD), although the reported prevalence rates vary between studies. This meta-analysis examined the overall prevalence of poor sleep quality in patients with PD and identified potential factors contributing to the differences in prevalence across studies.

Methods:

Both PRISMA and MOOSE guidelines were applied in this meta-analysis. A systematic search was conducted in PubMed, EMBASE, PsycINFO, Web of Science, CNKI and Wangfang from their inception to November 4, 2023. Studies were selected based on predefined PICOS criteria (i.e., PD patients, prevalence of poor sleep quality, cross-sectional/cohort designs). Study quality/risk of bias was assessed using a standardized 8-item tool. Pooled prevalence was calculated sources of heterogeneity (e.g., age, sex, depression, anxiety, cognition scores, disease severity, and medication dose) were explored via subgroup and meta-regression analyses. A random-effects model was utilized to calculate the overall prevalence and corresponding 95% confidence intervals (CIs).

Results:

In total, 63 studies involving 9,382 PD patients were included. The overall prevalence of poor sleep quality was 58.07% (95% CI: 54.26–61.88%). Higher rates were related to various factors including studies from Europe & Central Asia, Upper middle income countries, mixed patient sources, lower diagnostic cutoffs, and use of Movement Disorder Society PD criteria. Meta-regression analysis showed that late onset PD was associated with poorer sleep quality in patients with PD.

Conclusion:

Poor sleep quality is common in PD patients. Regular monitoring of sleep quality and promotion of sleep hygiene should be prioritized in the management of patients with PD. Additionally, further research on sleep and PD is warranted in low- and middle-income countries to ensure the applicability of findings across diverse populations.

Systematic Review Registration:

https://inplasy.com/inplasy-2023-10-0022/, identifier INPLASY2023100022.

1 Introduction

Parkinson’s disease (PD) is a progressive neurological disorder that interferes with the initiation and execution of voluntary movement, resulting in difficulty performing basic activities of daily living (1). PD is an age-related condition as its prevalence steadily increases with age (2). Although the cause is still unknown, many researchers believe that the disease is determined by the interaction between genetic and environmental factors, leading to a gradual degeneration of neurons in susceptible areas of the brain (2). Apart from the typical motor symptoms, non-motor symptoms in patients with PD, including sleep problems, autonomic dysfunction and sensory abnormalities (3), also have a significant impact on quality of life and overall health (4, 5).

Sleep problems in PD patients, such as poor sleep quality, are among the most prominent non-motor symptoms that considerably impact on the quality of life in both patients and caregivers (6, 7). The causes of sleep problems in PD patients involve disease-related factors such as dopaminergic medications, co-morbid mood disorders, and other related factors (8), as well as the associated symptoms and treatments of PD (9).

Poor sleep quality is one of the major sleep problems experienced by PD patients (10). Sleep quality is defined as one’s satisfaction with sleep experience, encompassing aspects such as sleep onset, sleep maintenance, subjective sleep quality, and mental state upon awakening (11). Both subjective and objective methods can be employed to assess sleep quality. Objective techniques usually have a high reliability in collecting sleep parameter data, such as using actigraphy and polysomnography (12). However, these objective sleep quality tests are costly, time-consuming, not easily accessible by most practitioners, and unsuitable for use in epidemiological studies and clinical practice (13). As such, subjective measures on sleep quality have been developed for such purposes, for instance, the Pittsburgh Sleep Quality Index (PSQI). The PSQI is the most utilized subjective measurement of sleep quality across different populations, providing scores that allow for categorization as “good” or “poor” (14, 15). In addition, the Parkinson’s Disease Sleep Scale (PDSS) is another widely used visual analog scale that addresses several symptoms associated with sleep disorders in PD, including sleep quality (16).

Previous studies on the prevalence of poor sleep quality in patients with PD have reported rates ranging from 20% to 88% (1719). In addition, poor sleep quality in PD patients has been found to be associated with more severe comorbid depressive and anxiety symptoms, reduced cognitive performance, and more severe PD symptoms (20). Therefore, to address the negative impact of poor sleep quality on PD patients, it is important to understand the epidemiological patterns of poor sleep quality and its associated factors in this population.

To date, no systematic review and meta-analysis have been published on the prevalence estimates of poor sleep quality in PD patients. To address this gap, this meta-analysis aimed to assess the global prevalence of poor sleep quality in PD patients and identify potential factors contributing to the differences in prevalence in this population.

2 Method

2.1 Search strategy

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Meta-analyses Of Observational Studies in Epidemiology (MOOSE) checklist were followed in conducting this meta-analysis (21). Three investigators (TLS, YYW and JXL) systematically and independently searched literature in the PubMed, EMBASE, PsycINFO, Web of Science, China National Knowledge Infrastructure (CNKI) and Wangfang databases from their inception date until November 4, 2023, using the following search items: “Parkinson disease “ AND (“Sleep Quality” OR “Qualities, Sleep” OR “Quality, Sleep” OR “Sleep Qualities” OR “quality of sleeping” OR “sleeping quality” OR “Pittsburgh sleep quality index” OR “PSQI”) AND (“prevalence” OR “epidemiology” OR “rate”). The study protocol was registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY; registration number: INPLASY2023100022).

2.2 Inclusion and exclusion criteria

The same three investigators (TLS, YYW and JXL) independently reviewed the titles and abstracts of relevant publications and then read the full texts of to assess eligibility. The inclusion criteria were developed using the PICOS acronym: Participants (P): patients with PD according to study-defined diagnostic criteria, such as the UK PD Society Brain Bank criteria (22) and the Movement Disorder Society (MDS) clinical diagnostic criteria for PD (23); Intervention (I): not applicable; Comparison (C): NR; Outcome (O): prevalence of poor sleep quality or having information that could generate an estimation of that prevalence, using standard tools, such as the PSQI, to measure the quality of the sleep; Study design (S): cross-sectional and cohort studies (only baseline data were analyzed in cohort studies) with accessible data published in English or Chinese journals. Exclusion criteria included reviews, systematic reviews, meta-analyses, case studies, and commentaries. Further, studies conducted specifically on PD samples with a primary sleep disorder (e.g., PD patients recruited from sleep clinics who suffered from insomnia disorder or obstructive sleep apnea (OSA)) were excluded to avoid the risk of overrepresenting sleep disturbances and selection bias in PD samples (24, 25). Only the study with the most detailed information was included in the meta-analysis if a dataset was utilized in more than one study (26).

2.3 Data extraction and quality assessment

Participant and study data, such as the first author, publication year, sampling method, sleep quality measures, number of PD patients, cut-off value, illness duration, number of participants with poor sleep quality, and sleep quality scores, mean age and male proportion of study sample, diagnostic criteria, were extracted. Additionally, to characterize the multidimensional aspects of sleep, we extracted specific components from standardized sleep tools (e.g., the PSQI domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medications, and daytime dysfunction).

Such components including sleep medication use could enable the evaluation of naturally occurring sleep within broadly representative PD cohorts, rather than selective studies that focused on sleep comorbidities and effects of treatment.

Study quality was assessed using a standardized instrument for epidemiological studies (27, 28) with the following eight items: (1) target population was defined clearly; (2) probability sampling or entire population surveyed; (3) response rate was ≥80%; (4) non-responders were clearly described; (5) sample was representative of the target population; (6) data collection methods were standardized; (7) validated criteria were used to diagnose PD; and (8) prevalence estimates were given with confidence intervals (CIs) and detailed by subgroups. The total score ranged from 0 to 8. Studies with a total score of “7–8” were considered as “high quality,” “4–6” as “moderate quality,” and “0–3” as “low quality” based on previous studies (25, 29, 30).

2.4 Statistical analyses

All the statistical analyses were conducted using R program (31). A random-effects model was used to synthesis the pooled prevalence of poor sleep quality and its 95% confidence intervals (95% CI) (32). I2 statistics were used to determine the degree of study heterogeneity, with 25%, 50%, and 75% tentatively indicating low, moderate, and high heterogeneity, respectively (33). Subgroup analyses for categorical variables (e.g., study regions, countries by economic status according to the World Bank’s criteria (34), study design, cut-off value signifying poor sleep quality, and patients resources), and meta-regression analysis for continuous variables (mean age, proportions of male, depression, anxiety and cognitive dysfunction respectively, mean scores of MoCA, mean scores of MMSE and mean scores of Hoehn and Yahr Staging, mean levodopa equivalent daily dose and quality assessment score) were conducted to explore the sources of potential heterogeneity. The Egger’s test was used to evaluate publication bias, and a visual funnel plot for asymmetry was also provided. If there was publication bias (P<0.05), a trim-and-fill analysis was used. Sensitivity analyses were carried out to assess the stability of results by individually eliminating each study. The significance level was set at 0.05 (two-tailed).

3 Results

3.1 Search results and study characteristics

Out of a total of 5,514 publications initially retrieved, 1,220 were excluded. The remaining 4,294 studies were screened for eligibility. By screening the titles and abstracts, we identified 451 potentially eligible studies. After screening the full text of these studies, we ultimately included 63 studies in this meta-analysis (see Figure 1).

Figure 1

As shown in Table 1, 63 studies covering a total of 9,382 participants were included, with the sample sizes ranging from 40 to 938. The mean age of participants ranged from 51.42 to 74.97 years, the mean disease duration ranged from 0.56 to 9 years, and the mean age at onset ranged from 48.49 to 64.57 years. Regarding the use of scales for sleep quality in the PD patients, 58 studies used the PSQI, 2 studies used the PDSS, 2 studies used the PDSS-1 (the first entry in the Parkinson’s Disease Sleep Scale), and 2 studies used the PDSS-2 (Parkinson’s Disease Sleep Scale-2). We applied quality assessment on all 63 studies, where one was rated “low quality” (1.89%), while 62 studies were rated as “moderate quality” (98.41%), with study quality assessment scores ranging from 3 to 6 (See Supplementary Table S1).

Table 1

Author and Reference NumberStudy siteStudy designSample sizeScaleCut-offMean age ± SD (Year)Mean disease duration ± SD (Year)Mean onset age ± SD (Year)Diagnostic criteriaMean MoCA total scores ± SDMean MMSE total scores ± SDMean UPDRS-3 scores ± SDMean LEDD ± SD (mg/d)Mean H&Y stage ± SDStudy quality score
Ma and Ren (76)Chinacross-sectional110PSQI>463.24.1NRUKPDS21.22 ± 4.22NRNRNRNR5
Chen, Zhang, Zhou, Yang and Feng (77)Chinacross-sectional60PSQI>463.08 ± 11.936.33 ± 3.73NRUKPDSNRNRNRNRNR4
Chen, Hu, Han, Zhang and Zhang (78)Chinacross-sectional48PSQI>5NRNRNRPD criteria by NEDC26.54 ± 3.85NR33.93 ± 19.82NR4.174
Chen, Hong and Chen (79)Chinacross-sectional265PSQI>763.1 ± 8.84.35 ± 2.12NRUKPDS24.53 ± 3.64NR20.51 ± 10.01NRNR4
Guo, Yu, Zuo, Liu, Li, Pu, Hu, Lian, Wang, Yu, Jin, Zhu and Zhang (80)Chinacross-sectional94PSQI>465.08 ± 2.235.15 ± 1.359.93 ± 2.01UKPDS21.58 ± 1.1826.55 ± 0.9419.09 ± 2.33NRNR4
Guo (81)Chinacross-sectional100PSQI>774.97 ± 6.848.87 ± 4.3NRUKPDSNRNRNRNRNR4
Yuan, Hu, Zhao, Wang, Zhang and Li (82)Chinacross-sectional83PSQI>769.04 ± 9.695.05 ± 3.463.99 ± 9.69Diagnostic criteria for PD in ChinaNRNR27.94 ± 18.17NRNR4
Xue (83)Chinacross-sectional50PSQI>672.36 ± 5.69NRNRDiagnostic criteria for PD in ChinaNRNRNRNRNR4
Hu and Zhang (84)Chinacross-sectional170PSQI>665.78 ± 9.14.08 ± 3.34NRUKPDSNR28.47 ± 1.6416.3 ± 8.48400 ± 2102.12 ± 1.254
Cheng, Yu and Wu (85)Chinacross-sectional95PSQI>752.53 ± 14.71NRNRDiagnostic criteria for PD in ChinaNRNRNRNRNR4
Wang, Feng, Gu, Liu and Chen (86)Chinacross-sectional486PSQI>662.52 ± 10.034.42 ± 3.6958.18 ± 10.41UKPDSNR27.33 ± 2.89NRNRNR5
Wang, Feng, Gu, Liu, Zhang and Chen (87)Chinacross-sectional535PSQI>664.24 ± 8.054.39 ± 3.8659.91 ± 8.76UKPDSNR27.17 ± 2.8921.01 ± 12.27NR2.04 ± 1.845
Wang and Wang (88)Chinacross-sectional45PSQI>464.07 ± 10.12.66 ± 2.2261.41 ± 10.18UKPDS22.66 ± 5.53NRNRNRNR5
Wang, Sun, Ma, Shi, Li, Huang, Hu and Zheng (89)Chinacross-sectional359PSQI>662.84 ± 7.816.25 ± 4.56NRDiagnostic criteria for PD in ChinaNRNR38.19 ± 28.9NRNR4
Mao and Zhang (90)Chinacross-sectional112PSQI>765.06 ± 6.496.39 ± 3.09NRDiagnostic criteria for PD in China21.83 ± 4.86NR40.05 ± 14.21NR1.674
Mao, Dai and Liu (91)Chinacross-sectional53PSQI>562.17 ± 9.264.91 ± 3.7857.7 ± 8.43UKPDSNRNRNRNR1.8 ± 0.44
Mao and Saimaiti (92)Chinacross-sectional46PSQI>5NRNRNRPD criteria by NEDC28.11 ± 2.91NR32.91 ± 16.13NRNR3
Liang, Cui, Wu, Yu and Chen (93)Chinacross-sectional120PSQI>662.73 ± 8.855.87 ± 2.87NRUKPDSNRNRNRNRNR4
Zhu, Zheng and Yang (94)Chinacross-sectional58PSQI>565.07 ± 8.15.26 ± 2.5NRPD criteria by NEDCNRNRNRNR1.6 ± 1.025
Cao, Liu, Ma, Chen, Ren, Zhang and Xu (95)Chinacross-sectional75PSQI>663.2 ± 10.263.11 ± 2.9258.24 ± 12.58MDS-PD19.53 ± 5.6924.41 ± 4.8031.93 ± 14.05NR1.85 ± 1.204
Cao, Yu, Su and Guo (96)Chinacross-sectional93PSQI>567.58 ± 8.143.01 ± 2.7464.57 ± 8.67UKPDSNR26.44 ± 1.03NRNR2.47 ± 0.984
Zhang, Gao and Wei (97)Chinacross-sectional68PSQI>661.23 ± 7.13.78 ± 3.12NRUKPDSNRNRNRNRNR4
Zhang, Zhang, Zhu, Jiang and Wu (98)Chinacross-sectional253PSQI>668.84 ± 11.114.75 ± 4.263.95 ± 11.18UKPDS20.77 ± 5.0225.31 ± 4.1027.88± 16.64333.76 ± 327.31NR4
Zhang, Liu, Wang, Liu and Gu (99)Chinacross-sectional127PSQI>566.38 ± 9.45.02 ± 3.6NRMDS-PDNRNRNRNR2.44 ± 0.525
Zhang, Luo and Liao (100)Chinacross-sectional95PSQI>6NR6.38 ± 4.3861.51 ± 7.48UKPDS18.33 ± 3.4020.75 ± 2.9435.44 ± 17.05NRNR4
Cui, Qing, Liu and Chen (101)Chinacross-sectional138PSQI>4NRNRNRUKPDS26.87 ± 1.83NRNRNRNR5
song, Zhao, Li and Yin (102)Chinacross-sectional40PSQI>763.85 ± 8.654.91 ± 3.51NRDiagnostic criteria for PD in ChinaNR48.46 ± 23.25NRNR2.84 ± 1.294
Song, Sun, Ma, Lu, Fan, Wang, Wang and Wang (103)Chinacross-sectional80PSQI9 or above66.82 ± 7.65NRNRUKPDSNRNR22.81 ± 4.19NRNR5
Sun, Gao, Mo and Gong (104)Chinacross-sectional56PSQI>655.77 ± 11.013.52 ± 2.8651.86 ± 10.88UKPDSNRNR25.68 ± 13.96NR1.944
Lv, Wang, Zhu, Zhao and Guo (18)Chinacross-sectional135PSQI>651.42 ± 14.632.35 ± 1.03NRDiagnostic criteria for PD in ChinaNRNR18.91 ± 5.21NR3.69 ± 0.535
Lu (105)Chinacross-sectional70PSQI>764 ± 49 ± 4NRUKPDSNRNRNRNRNR4
Liu and Chen (106)Chinacross-sectional82PSQI>564.21 ± 11.243.24 ± 1.45NRUKPDSNRNR15.03 ± 8.61NR1.85 ± 0.974
Liu, Li, Fang, Qin and Wei (107)Chinacross-sectional97PSQI>461.7 ± 9.22.1 ± 0.762.1 ± 9.7PD criteria by NEDCNRNR22.7 ± 8.9432.3 ± 207.22.1 ± 0.64
Liu, Chou, Ma, Zhang, Wang and Gu (108)Chinacross-sectional71PSQI>566.5 ± 8.666.11 ± 4.05NRUKPDS22.03 ± 5.0626.56 ± 3.10NRNR2.4 ± 0.85
Liu, Wang, Wang, Mao and Wang (109)Chinacross-sectional502PSQI>7NRNRNRUKPDSNRNRNRNRNR4
YU, PENG, LUO, HUANG and WANG (110)Chinacross-sectional100PSQI>760.3 ± 8.264.24 ± 1.26NRDiagnostic criteria for PD in China21.89 ± 4.70NRNRNRNR4
Yi, Yu-Peng, Jiang-Ting, Jing-Yi, Qi-Xiong, Dan-Lei, Jing-Wei, Zhi-Juan, Yong-Jie, Zhe and Zheng (111)Chinacross-sectional328PSQI9 or above60.5 ± 10.14.78 ± 4.2755.53 ± 10.34MDS-PDNR25.19 ± 4.8332.23 ± 17.30575.78 ± 245.082.16 ± 0.995
Wang, Xiong, Chao, Zhuang, Li and Liu (112)Chinacross-sectional938PSQI>5NRNRNRUKPDSNRNRNRNRNR5
Tang, Yang, Zhu, Gong, Sun, Chen, Guan, Yu, Wang, Zhang, Li, Ma and Wang (113)Chinacross-sectional61PSQI>566.6 ± 6.104.5 ± 3.6361.6 ± 7UKPDS26.38 ± 3.3328.75 ± 2.2222.63 ± 10409.23 ± 249.562.45 ± 0.895
Song, Gu, An and Chan (114)Chinacohort284PSQI>5NRNRNRUKPDSNRNRNRNRNR4
Shulman, Taback, Bean and Weiner (115)United Statescross-sectional99PSQI>567.4 ± 86.9 ± 5.7NRUKPDSNRNR22 ± 9NR2.3 ± 0.86
Santos García, Cabo López, Labandeira Guerra, Yáñez Baña, Cimas Hernando, Paz González, Alonso Losada, Gonzalez Palmás, Cores Bartolomé and Martínez Miró (19)Spaincross-sectional47PSQI>5NRNRNRUKPDSNRNRNRNRNR4
Sahebzadeh, Farsi Baf and Homam (116)Irancross-sectional120PSQI>565.9 ± 11.72.6 ± 2.7NRUKPDS17.39 ± 5.20NRNRNRNR6
Qiu, Gu, Liu and Li (117)Chinacross-sectional101PSQI9 or above61.25 ± 7.837.82 ± 1.34NRDiagnostic criteria for PD in ChinaNRNRNRNRNR4
Qin, Li, Chen, Chen, Shi, Liu, Li, Xin and Gao (118)Chinacross-sectional110PSQI>766.82 ± 8.233.67 ± 4.0361.25 ± 10.38MDS-PDNRNR20.68 ± 18.02447.32 ± 230.352.01 ± 0.874
Pandey, Bajaj, Wadhwa and Anand (17)Indiacross-sectional100PSQI>559.2 ± 9.063.74 ± 3.6755.5 ± 9.68UKPDSNRNR21.16 ± 6.98367.53 ± 300.162.26 ± 0.644
Mahale, Yadav and Pal (119)Indiacross-sectional156PSQI>552.47 ± 14.635.65 ± 4.6448.49 ± 13.8UKPDSNR27.73 ± 2.2128.81 ± 10.77602.73 ± 353.302.23 ± 0.514
Louter, van der Marck, Pevernagie, Munneke, Bloem and Overeem (120)Chinacross-sectional153PSQI>565.9 ± 9.77.7 ± 5.7NRUKPDSNRNRNR468.4 ± 336.52.174
Lin, Chen, Lu, Huang, Weng, Yeh, Lin and Hung (121)Taiwancross-sectional225PSQI>565.7 ± 8.888.18 ± 5.257.5 ± 9.9UKPDSNRNR22.77 ± 10.8425.84 ± 324.92NR5
Havlikova, van Dijk, Nagyova, Rosenberger, Middel, Dubayova, Gdovinova and Groothoff (122)Slovak Republiccross-sectional93PSQI>468 ± 9.56.1 ± 5.9NRUKPDSNRNR15.88 ± 10.43NR2 ± 1.25
Gao, Huang, Cai and Li (123)Chinacross-sectional88PSQI>564.03 ± 10.55.41 ± 3.75NRMDS-PDNR25.59 ± 2.9924.63 ± 7.58510.85 ± 224.612.57 ± 14
Duncan, Khoo, Yarnall, O’Brien, Coleman, Brooks, Barker and Burn (124)United Kingdomcohort158PSQI>566.5 ± 10.30.56 ± 0.49NRUKPDS25.1 ± 3.628.6 ± 1.427.1 ± 12NR1.784
Ding, Zhu, Lu, Shen, Dai and Zhu (125)Chinacross-sectional75PSQI9 or above64.46 ± 6.46NRNRPD criteria by NEDCNRNR23.70 ± 3.81NRNR4
Shafazand, Wallace, Arheart, Vargas, Luca, Moore, Katzen, Levin and Singer (126)United Statescross-sectional66PSQI>564.00 ± 10.00NRNRUKPDSNRNRNR363.20 ± 255.30NR4
Skorvanek, Nagyova, Rosenberger, Krokavcova, Saeedian, Groothoff, Gdovinova and van Dijk (127)Slovenská republikacross-sectional165PSQI>669.59 ± 8.566.93 ± 4.80NRUKPDSNRNR30.11 ± 13.62NR2.41 ± 0.894
Shi, Guan, Gao, Huang and Wang (128)Chinacross-sectional120PSQI9 or above58.02 ± 8.565.48 ± 1.72NRDiagnostic criteria for PD in ChinaNRNR27.94 ± 8.98NR3.12 ± 1.224
Dong and Tan (129)Chinacross-sectional92PSQI>769.77 ± 9.802.89 ± 4.00NRDiagnostic criteria for PD in ChinaNRNR24.84 ± 18.67333.70 ± 134.802.27 ± 0.744
Chang, Fan, Chang and Wu (130)Taiwancross-sectional134PDSS-2>1664.98 ± 9.197.86 ± 5.5557.29 ± 10.66UKPDSNR27.44 ± 1.8823.91 ± 11.92647.39 ± 491.491.43 ± 0.644
Shi (131)Chinacross-sectional95PDSS-2>1267.81 ± 5.934.1 ± 0.71NRDiagnostic criteria for PD in ChinaNRNRNRNRNR4
Li, Yuan, Ye, Yuan, Gao and Hu (132)Chinacross-sectional87PDSS<9166.99 ± 7.185.75 ± 3.9461.77 ± 7.84Diagnostic criteria for PD in ChinaNR27.58 ± 2.6914.70 ± 5.25490.78 ± 219.78NR4
Gui, Wang, Wu and Sun (133)Chinacross-sectional178PDSS<9161.81 ± 10.924.50 ± 3.4856.53 ± 10.98UKPDSNR26.61 ± 5.4129.31 ± 14.66441.26 ± 299.591.92 ± 0.754
Hu, Sun, Lan, Wang, Li and Zhong (134)Chinacross-sectional207PDSS-1<661.29 ± 9.714.43 ± 4.74NRPD criteria by NEDC16.97 ± 6.1823.50 ± 5.45NRNR2.34 ± 0.854
Niu and Gou (135)Chinacross-sectional131PDSS-1<662.20 ± 8.002.27 ± 1.41NRDiagnostic criteria for PD in ChinaNRNRNRNRNR4

Characteristics of studies included in the meta-analysis.

NR, not reported; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; H&Y stage, Hoehn and Yahr stage; UKPDS, UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria; MDS-PD, Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease; PD criteria by NEDC, Parkinson’s diagnostic criteria established by Chinese Medical Association in the National Extrapyramidal Disorders Conference; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; UPDRS-3, The Unified Parkinson’s Disease Rating Scale part 3 (Motor Examination); LEDD, Levodopa equivalent daily dose; PSQI, Pittsburgh Sleep Quality Index; PDSS, Parkinson’s Disease Sleep Scale; PDSS-1, First item of Parkinson’s Disease Sleep Scale; PDSS-2, Parkinson’s disease sleep scale-2.

3.2 Pooled prevalence of poor sleep quality, PSQI global scores and PSQI component scores in Parkinson’s disease patients

Based on the 63 studies, the pooled prevalence of poor sleep quality in PD patients was 58.07% (95% CI: 54.26–61.88%) (Figure 2). As shown in Table 2, 28 studies with 3,369 participants reported PSQI global scores among PD patients, with a pooled PSQI total score of 8.6 (95% CI: 7.66-9.55). The seven PSQI sleep component scores were reported in 6 studies (N=540). The pooled PSQI component scores ranged from 0.73 (95% CI: 0.31-1.16) for “sleep medication use” to 1.76 (95% CI: 1.38-2.14) for “daytime dysfunction” (see Table 2).

Figure 2

Table 2

VariablesNumber of studiesSample sizePooled mean score (95% CI)I2P values
PSQI global score2833698.6101 (7.6664; 9.5538)98.80%< 0.0001
Subjective sleep quality65401.3010 (0.9834; 1.6187)94.50%< 0.0001
Sleep latency65401.3541 (0.9200; 1.7883)97.40%< 0.0001
Sleep duration65401.1770 (0.9375; 1.4164)87.50%< 0.0001
Habitual sleep efficiency65400.9736 (0.6394; 1.3078)93.30%< 0.0001
Sleep disturbance65401.4194 (1.2180; 1.6208)91.80%< 0.0001
Use of sleep medications65400.7347 (0.3085; 1.1609)98.40%< 0.0001
Daytime dysfunction65401.7561 (1.3769; 2.1354)96.50%< 0.0001

The pooled PSQI global and sleep component score in Parkinson’s disease patients.

3.3 Subgroup and meta-regression analyses

Subgroup analysis by comparing means showed that study site was significantly associated with the prevalence of poor sleep quality (p < 0.01). Specifically, the highest prevalence of poor sleep quality in PD patients was reported in studies conducted in Europe & Central Asia (59.65% 95%CI: 37.63-81.68%), while the lowest figure was reported in North America (47.88%, 95%CI: 40.26–55.50%). There was also a significant subgroup difference in prevalence of poor sleep quality between countries by income (P <0.01): the highest prevalence was reported in upper-middle income countries (58.37%, 95%CI: 54.35–62.39%), while the lowest prevalence was reported in high income countries (56.40%, 95%CI: 40.51–72.28%). There were significant subgroup differences between PD diagnostic criteria (P < 0.01); the pooled prevalence of poor sleep quality was 59.04% (95% CI: 54.18-63.89%) in studies using the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria (UKPDS), 59.11% (95% CI: 40.65-77.57%) in studies using the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease (MDS-PD), 57.20% (95% CI: 49.03-65.37%) in studies using the Diagnostic criteria of Chinese Parkinson’s Disease & Movement Disorders Society, Society for Neurology, Chinese Medical Association (Diagnostic criteria for PD in China) and 52.83% (95% CI: 42.44-63.22%) in studies using the diagnostic criteria for Parkinson’s disease established by the National Extrapyramidal Disorders Conference (PD criteria by NEDC). Furthermore, the pooled prevalence rates of poor sleep quality were 60.57% (95% CI: 50.23-70.91%) in inpatients, 53.66% (95% CI: 45.21-62.11%) in outpatients, and 62.86% (95% CI: 53.72-72.00%) in the mixed group. Moreover, there were significant differences (p < 0.01) between studies using different measures on sleep quality; the prevalence of poor sleep quality was 59.14% (95% CI: 55.19-63.09%) in studies using the PSQI, 40.96% (95% CI: 18.33-63.58%) in studies using the PDSS, 56.16% (95% CI: 22.69-89.62%) in studies using PDSS-1, and 47.16% (95% CI: 40.70-53.63%) in the studies using PDSS-2 (Table 3). In meta-regression analyses, onset age (β=0.0132, z=2.0704, p=0.0384) was positively associated with the prevalence of poor sleep quality. However, mean age, illness duration, levodopa equivalent daily dose, and The Unified Parkinson’s Disease Rating Scale part 3 (Motor Examination) score were not found to be statistically significant in the meta-regression (Table 3).

Table 3

Subgroup analysis
SubgroupsCategoriesNo. of studiesPrevalence (95%CI)I2P values within subgroupsP values across subgroups
Geographic regionEast Asia & Pacific5358.37% (54.35-62.39%)94%<0.01<0.01
Europe & Central Asia559.65% (37.61-81.68%)97%<0.01
South Asia248.04% (41.93-54.16%)0%0.62
North America247.88% (40.26-55.50%)0%0.9
Countries by incomeUpper middle income5358.37% (54.35-62.39%)94%<0.01<0.01
High income756.40% (40.51-72.28%)96%<0.01
Lower middle income356.51% (40.51-72.51%)91%<0.01
Study designCross-sectional6158.24% (54.32-62.16%)94%<0.01<0.01
Cohort253.29% (41.23-65.35%)84%0.01
Diagnostic criteriaUKPDS3859.04% (54.18-63.89%)94%<0.01<0.01
MDS-PD559.11% (40.65-77.57%)98%<0.01
Diagnosticcriteria for PD in China1457.20% (49.03-65.37%)93%<0.01
PD criteria by NEDC652.83% (42.44-63.22%)83%<0.01
Cut-off value*>4, >5, >6 and4159.61% (54.87-64.35%)94%<0.01<0.01
>7 or above 71657.93% (50.64-65.22%)95%<0.01
Patient sourceMixed1562.86% (53.72-72.00%)95%<0.01<0.01
Inpatients360.57% (50.23-70.91%)77%0.01
Outpatients1253.66% (45.21-62.11%)96%<0.01
ScalePSQI5759.14% (55.19-63.09%)94%<0.01<0.01
PDSS240.96% (18.33-63.58%)92%<0.01
PDSS-1256.16% (22.69-89.62%)98%<0.01
PDSS-2247.16% (40.70-53.63%)0%0.83
Meta-regression analyses
VariablesNumber of studiesCoefficientStandard Error95% Lower95% Upperz valuesP values
Mean age550.00760.0048-0.00170.01691.59490.1107
Illness duration510.01050.0124-0.01390.03480.84150.4001
Male proportion59-0.12650.2418-0.60050.3474-0.52330.6008
Onset age210.01320.00640.00070.02582.07040.0384
MoCA16-0.00470.0115-0.02720.0178-0.40750.6836
MMSE19-0.00440.0073-0.01860.0099-0.60440.5456
UPDRS-3330.00680.0043-0.00170.01531.55800.1192
LEDD mean16-0.00060.0004-0.00140.0002-1.51780.1291
H&YStage31-0.01260.0547-0.11980.0946-0.23040.8178
Study quality63-0.06820.0348-0.1363-0.0001-1.96180.0498

Subgroup analyses and meta-regression analyses.

*Only the study using the PSQI;H&Y stage: Hoehn and Yahr stage; UKPDS, UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria; MDS-PD, Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease; PD criteria by NEDC, Parkinson’s diagnostic criteria established by the National Extrapyramidal Disorders Conference; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; UPDRS-3, The Unified Parkinson’s Disease Rating Scale part 3 (Motor Examination); H&Y stage, Hoehn and Yahr stage; LEDD, Levodopa equivalent daily dose; PSQI, Pittsburgh Sleep Quality Index; PDSS, Parkinson’s Disease Sleep Scale; PDSS-1, First item of Parkinson’s Disease Sleep Scale; PDSS-2, Parkinson’s disease sleep scale-2.

3.4 Publication bias and sensitivity analyses

The funnel plot assessment and Egger’s test value suggested no significant publication bias (Egger’s test t = 1.42, P= 0.1608) (See Supplementary Figure S1). Sensitivity analyses did not identify any outlying studies that could significantly change primary results (See Supplementary Figure S2). To avoid selection bias, no studies were excluded based solely on quality assessment. Sensitivity analysis confirmed that low-quality studies did not significantly alter the pooled prevalence estimates.

4 Discussion

To the best of our knowledge, this was the first systematic review and meta-analysis to examine the prevalence of poor sleep quality in patients with PD. Based on 63 studies, comprising 9,382 PD patients, the prevalence of poor sleep quality in patients with PD was 58.07% (95% CI: 54.26-61.88%). The factors associated with the prevalence of poor sleep quality included study region, income, diagnostic criteria, patient source and PD age of onset.

The pooled PSQI global score in this study was 8.61 (95% CI: 7.67-9.55), which was higher than the findings reported in most other population studies. For example, the global PSQI scores in a general population sample were 3.18 ± 2.28 in Japan (35), 5.00 ± 3.37 in Germany (36), 5.14 ± 3.90 in Spain (37), and 5.5 ± 2.8 in Singapore (38). The overall prevalence of poor sleep quality in PD patients was 58.07% (95% CI: 54.26-61.88%), which is substantially higher than most figures reported in other populations, including Singaporean working population (42.5%; 95% CI: 37.9-47.1%) (38), Chinese elderly population (35.9%; 95% CI: 30.6%-41.2%) (39), perinatal and postpartum women (54.2%; 95% CI: 47.9-60.5%) (24), medical students (55%; 95% CI 48.0%-62.0%) (40), patients with tinnitus (53.5%; 95% CI: 40.2-66.8%) (41), and patients with irritable bowel syndrome (37.6%; 95% CI: 31.4-44.3%) (42).

The high prevalence of poor sleep quality in PD patients may be attributed to the disease characteristics. Degenerative changes in the brain associated with the disease can directly impact sleep/wake mechanisms, leading to sleep disruptions (43). Additionally, movement difficulties, such as the inability to move around in bed, involuntary movements, dystonia, and pain caused by leg spasms, all of which can interfere with sleep maintenance (44). However, the overall prevalence of poor sleep quality in PD patients is lower than the rates reported in patients with chronic non-cancer pain (75.3%, 95% CI: 62.8-87.8%) (45), and hemodialysis patients (75.30%, 95% CI: 70.08-82.50%) (46). The prevalence is also lower than that in certain occupational groups with high work demands, such as nurses (61.00%, 95% CI: 55.8-66.1%) (47) and military personnel (69.00%, 95% CI: 62.33-75.30%) (25), who often experience high stress, shift work, long work hours, high burnout, and exposure to trauma (48).

In subgroup analyses, we found that the overall prevalence of poor sleep quality in PD patients was significantly lower in North America (47.88%, 95% CI: 40.26-55.50%) and high-income countries (56.40%, 95% CI: 40.51-72.28%) compared to other regions and countries. The burden of PD appears to be greater in low-income areas, which may contribute to poorer sleep quality (49, 50). On the other hand, higher-income countries may have access to better healthcare facilities, resources, and support, which can indirectly lower the risk of poor sleep quality PD patients (51). Greater healthcare resources in high-income countries may lead to more effective management of symptoms in PD patients in these countries, and thereby improving their sleep quality.

The overall prevalence of poor sleep quality was significantly higher among inpatients (60.57%, 95% CI: 50.23-70.91%) compared to outpatients (53.66%, 95% CI: 45.21-62.11%), which may be attributed to the severity of PD. Hospitalized patients usually suffer from a more advanced stage of the disease, necessitating closer medical monitoring and treatment (52). Certain symptoms, such as tremors, muscle stiffness, and difficulties with motor control, can all contribute to disrupted sleep (53, 54). Furthermore, changes in the environment such as being hospitalized or separated from their families and regular living environment can also contribute to a decline in sleep quality (55, 56). Consequently, hospitalized PD patients are more likely to encounter sleep problems.

In the subgroup analyses, the pooled prevalence of poor sleep quality in studies using the MDS-PD (59.11%, 95% CI: 40.65-77.57%) was significantly higher than those using the diagnostic PD criteria by NEDC (52.83%, 95% CI: 42.44-63.22%). Notably, certain studies had applied the UK Parkinson’s Disease Society Brain Bank (UKPDS) criteria and the Parkinson’s diagnostic criteria established by Chinese Medical Association (CMA) in the National Extrapyramidal Disorders Conference (NEDC), both of which differ from the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease(MDS-PD) in terms of diagnostic strictness and clinical application. Such diagnostic variations represent a key source of heterogeneity: the MDS-PD incorporates advanced biomarkers and updated clinical features to maximize specificity (23), whereas the UKPDS relies primarily on classic motor symptoms with established high sensitivity but lower specificity for early PD. The CMA guidelines adapt international standards to regional practices, potentially introducing operational variability, and NEDC (1984) lacks contemporary validation with possible under-identification of non-motor phenotypes (57, 58). Such methodological heterogeneity can directly influence prevalence estimates, as stricter criteria (e.g., MDS-PD) may capture patients with more advanced pathology and higher comorbidity burden, while broader criteria (e.g., NEDC/UKPDS) can include borderline cases with milder sleep disturbances. Consequently, the observed prevalence differences likely reflect both true biological variability and diagnostic threshold effects, necessitating cautious interpretation of cross-criteria study comparisons.

Subgroup analyses also revealed significantly higher pooled prevalence rates in cross-sectional studies (58.24%, 95% CI: 54.32-62.16%) compared to cohort studies (53.29%, 95% CI: 41.23-65.35%). It should be noted that only a small number of cohort studies (n = 2) were included, which might have resulted in less reliable estimates. Similarly, the higher prevalence observed in studies using the PSQI might partially reflect selection bias, due to the small number of studies using the PDSS (n = 2), PDSS-1 (n = 2), and PDSS-2 (n=2). Therefore, the findings of these subgroup analysis are tentative.

In meta-regression analyses, the age of onset of PD was positively associated with prevalence of poor sleep quality. Previous studies found that gender and age of onset are significant factors influencing the clinical phenotype of PD, affecting both motor symptoms and various non-motor symptoms (59). Patients with late-onset PD tend to experience more frequent non-motor symptoms, including cognitive dysfunction, autonomic dysfunction, and sleep disturbances (60, 61). A study conducted in China on non-motor symptoms in PD found positive correlations between age, daily levodopa dose, and Non-Motor Symptoms Scale (NMSS) scores in patients with late-onset PD. However, these correlations were not observed in those with early-onset PD, suggesting that age and daily levodopa dose may play a more significant role in the severity of non-motor symptoms in patients with late-onset PD compared to those with early-onset PD (62). Several brainstem nuclei are potentially involved in the mechanisms underlying non-motor symptoms such as gastrointestinal regulation, pain perception, emotion control, and sleep-wake cycles (63, 64). The presence of Lewy bodies, which are composed of abnormal α-synuclein and are found outside the dopaminergic neurons of the midbrain, probably contribute to the pathology of non-motor manifestations in PD (63, 65, 66). Different distribution and severity of central nervous system lesions and pathophysiological course of PD between patients with early-onset and late-onset PD may be crucial factors influencing the non-motor features (e.g., sleep quality) associated with the disease (62).

Overall, our meta-analysis indicates that patients with PD have a high prevalence of poor sleep quality. Sleep problems are closely associated with mental health (67), and patients with PD often experience psychological stress (68), anxiety and depression (69, 70). Therefore, maintaining good sleep quality plays a crucial role in sustaining emotional and mental stability and enhancing the mental well-being and quality of life for patients (71). Cognitive decline and difficulties with concentration are common challenges faced by PD patients (72, 73). Prioritizing sleep quality in patients with PD is essential for managing symptoms, enhancing mental health, and preserving cognitive functioning. By optimizing the sleep environment, establishing healthy sleep habits, and utilizing medications or other treatments, when necessary, the sleep quality of patients with PD can be improved. Moreover, meta-regression showed that study quality was negatively associated with sleep quality in PD patients. Thus, lower study quality may lead to underestimation of sleep problems in PD patients. Improving the methodological rigor of studies may help to more accurately assess the severity of sleep quality problems (74).

Strengths of this meta-analysis include high number of included studies and large sample size, and the utilization of comprehensive analytical methods, such as subgroup and meta-regression analyses, to identify factors associated with poor sleep quality. Nonetheless, several limitations should be noted. First, despite use of sophisticated statistical methods, heterogeneity still remained in the subgroup analyses, as is expected in meta-analyses of epidemiological surveys, as pointed out in previous studies (25, 47). Second, certain factors related to poor sleep quality, such as living environment, psychiatric comorbidities, and educational background, were not included in most studies. Third, wide confidence intervals for subgroups might be related to small sample sizes or the use of different PD diagnostic criteria in some studies. Fourth, the overrepresentation of Chinese studies might introduce bias that could affect the generalizability of the findings to other populations (75). Fifth, while our analysis identified key correlates of poor sleep quality, the preponderance of cross-sectional data precluded any causal conclusions. Longitudinal studies are warranted to explore the temporal relationships, particularly between sleep deterioration and PD progression trajectories. Furthermore, significant heterogeneity in PD diagnostic criteria (e.g., MDS-PD vs. UKPDS vs. CMA vs. NEDC) could result in methodological variability. Although this reflects real-world clinical practice, differences in diagnostic sensitivity/specificity might influence pooled prevalence estimates and subgroup comparability. Future meta-analyses would benefit from standardized application of contemporary diagnostic frameworks of PD.

In conclusion, poor sleep quality is common among patients with PD, particularly in lower middle-income countries and Europe & Central Asia regions. To mitigate the adverse effects of poor sleep quality in PD patients, regular monitoring of sleep quality and sleep hygiene is crucial, particularly in high-risk subgroups. Additionally, further studies of sleep quality and PD patients in low- and middle-income countries are warranted, as well as prospective cohort studies to clarify the causality between poor sleep quality and other factors.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

TS: Conceptualization, Data curation, Formal Analysis, Methodology, Writing – original draft, Writing – review & editing. YW: Data curation, Formal Analysis, Methodology, Writing – review & editing. JL: Data curation, Formal Analysis, Methodology, Writing – review & editing. WB: Data curation, Formal Analysis, Methodology, Writing – review & editing. HS: Writing – review & editing. SR: Data curation, Writing – review & editing. HZ: Data curation, Writing – review & editing. GU: Writing – review & editing. ZS: Data curation, Writing – review & editing. TC: Data curation, Writing – review & editing. CN: Conceptualization, Writing – review & editing. YX: Conceptualization, Writing – original draft, Writing – review & editing. GW: Data curation, Methodology, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. The study was supported by Beijing High Level Public Health Technology Talent Construction Project (Discipline Backbone-01-028), the Beijing Municipal Science & Technology Commission (No. Z181100001518005), and the Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (XMLX202128) and the University of Macau (MYRG2019-00066-FHS; MYRG2022-00187-FHS).

Acknowledgments

The authors are grateful to all participants and clinicians involved in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1606743/full#supplementary-material

Supplementary Table 1

Quality assessment of included studies.

Supplementary Figure 1

Funnel plot of pooled prevalence of poor sleep quality in Parkinson’s disease patients.

Supplementary Figure 2

Sensitivity analysis of pooled prevalence of poor sleep quality in Parkinson’s disease patients.

References

  • 1

    TriegaardtJHanTSSadaCSharmaSSharmaP. The role of virtual reality on outcomes in rehabilitation of Parkinson’s disease: meta-analysis and systematic review in 1031 participants. Neurol Sci. (2020) 41:529–36. doi: 10.1007/s10072-019-04144-3

  • 2

    PringsheimTJetteNFrolkisASteevesTDL. The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Movement Disord. (2014) 29:1583–90. doi: 10.1002/mds.25945

  • 3

    PfeifferRF. Non-motor symptoms in Parkinson’s disease. Parkinsonism Related Disord. (2016) 22:S119–22. doi: 10.1016/j.parkreldis.2015.09.004

  • 4

    Martinez-MartinPRodriguez-BlazquezCKurtisMMChaudhuriKRGroup oBotNV. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disord. (2011) 26:399406. doi: 10.1002/mds.23462

  • 5

    PrakashKMNadkarniNVLyeW-KYongM-HTanE-K. The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol. (2016) 23:854–60. doi: 10.1111/ene.12950

  • 6

    StavitskyKCronin-GolombA. Sleep quality in Parkinson disease: an examination of clinical variables. Cognit Behav Neurol. (2011) 24:43–9. doi: 10.1097/WNN.0b013e31821a4a95

  • 7

    ComellaCL. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl. (2006) 70):349–55. doi: 10.1007/978-3-211-45295-0_53

  • 8

    NajafiMRChitsazAAskarianZNajafiMA. Quality of sleep in patients with Parkinson’s disease. Int J Prev Med. (2013) 4:S229–33. doi: 10.1186/s12883-024-03548-9

  • 9

    SchrempfWBrandtMDStorchAReichmannH. Sleep disorders in parkinson’s disease. J Parkinson’s Dis. (2014) 4:211–21. doi: 10.3233/JPD-130301

  • 10

    Santos-GarcíaDCastroESde Deus FonticobaTPanceirasMFEnriquezJMGonzálezJPet al. Sleep problems are related to a worse quality of life and a greater non-motor symptoms burden in parkinson’s disease. J Geriatric Psychiatry Neurol. (2021) 34:642–58. doi: 10.1177/0891988720964250

  • 11

    KlineC. Sleep quality. In: GellmanMDTurnerJR, editors.Encyclopedia of Behavioral Medicine. Springer, New York (2013). p. 1811–3.

  • 12

    KrystalADEdingerJD. Measuring sleep quality. Sleep Med. (2008) 9:S10–7. doi: 10.1016/S1389-9457(08)70011-X

  • 13

    FabbriMBeracciAMartoniMMeneoDTonettiLNataleV. Measuring subjective sleep quality: A review. Int J Environ Res Public Health. (2021) 18:1082. doi: 10.3390/ijerph18031082

  • 14

    BuysseDJReynoldsCFMonkTHBermanSRKupferDJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. (1989) 28:193213. doi: 10.1016/0165-1781(89)90047-4

  • 15

    LandryGJBestJRLiu-AmbroseT. Measuring sleep quality in older adults: a comparison using subjective and objective methods. Front Aging Neurosci. (2015) 7:166. doi: 10.3389/fnagi.2015.00166

  • 16

    TseWinonaLiuYimingBarthlenGabriele MHälbigThomas DTolgyesiSonia VGraciesJean-Michel. Clinical usefulness of the Parkinson’s disease sleep scale. Parkinsonism Related Disord. (2005) 11:317–21. doi: 10.1016/j.parkreldis.2005.02.006

  • 17

    PandeySBajajBKWadhwaAAnandKS. Impact of sleep quality on the quality of life of patients with Parkinson’s disease: a questionnaire based study. Clin Neurol Neurosurg. (2016) 148:2934. doi: 10.1016/j.clineuro.2016.06.014

  • 18

    LvDWangXZhuYZhaoLGuoQ. Clinical analysis of parkinson’s disease with anxiety, depression and sleep disorders. Clin Misdiagn Misther. (2019) 32:83–8. doi: 10.3969/j.issn.1002-3429.2019.02.019

  • 19

    Santos GarcíaDCabo LópezILabandeira GuerraCYáñez BañaRCimas HernandoMIPaz GonzálezJMet al. Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study. Neurol Sci. (2022) 43:2537–44. doi: 10.1007/s10072-021-05607-2

  • 20

    JunhoBTKummerACardosoFETeixeiraALRochaNP. Sleep quality is associated with the severity of clinical symptoms in Parkinson’s disease. Acta Neurol Belgica. (2018) 118:8591. doi: 10.1007/s13760-017-0868-6

  • 21

    PageMatthew JMcKenzieJoanne EBossuytPatrick MBoutronIsabelleHoffmannTammy CMulrowCynthia Det al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PloS Med. (2021) 18:e1003583. doi: 10.1371/journal.pmed.1003583

  • 22

    DanielSLeesA. Parkinson’s Disease Society Brain Bank, London: overview and research. J Neural Transm Supplementum. (1993) 39:165–72.

  • 23

    PostumaRBBergDSternMPoeweWOlanowCWOertelWet al. MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disord. (2015) 30:1591–601. doi: 10.1002/mds.26424

  • 24

    YangYLiWMaTJZhangLHallBJUngvariGSet al. Prevalence of poor sleep quality in perinatal and postnatal women: A comprehensive meta-analysis of observational studies. Front Psychiatry. (2020) 11:161. doi: 10.3389/fpsyt.2020.00161

  • 25

    BaiWGuiZChenMYZhangQLamMISiTLet al. Global prevalence of poor sleep quality in military personnel and veterans: A systematic review and meta-analysis of epidemiological studies. Sleep Med Rev. (2023) 71:101840. doi: 10.1016/j.smrv.2023.101840

  • 26

    DongMWangSBLiYXuDDUngvariGSNgCHet al. Prevalence of suicidal behaviors in patients with major depressive disorder in China: A comprehensive meta-analysis. J Affect Disord. (2018) 225:32–9. doi: 10.1016/j.jad.2017.07.043

  • 27

    BoyleMH. Guidelines for evaluating prevalence studies. Evid Based Ment Health. (1998) 1:37–9. doi: 10.1136/ebmh.1.2.37

  • 28

    LoneyPLChambersLWBennettKJRobertsJGStratfordPW. Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Canada. (1998) 19:170–6.

  • 29

    CaiHChenPZhangQLamMISiTLLiuYFet al. Global prevalence of major depressive disorder in LGBTQ+ samples: A systematic review and meta-analysis of epidemiological studies. J Affect Disord. (2024) 360:249–58. doi: 10.1016/j.jad.2024.05.115

  • 30

    ChenPLamMISiTLZhangLBalbuenaLSuZet al. The prevalence of poor sleep quality in thegeneral population in China: a meta-analysis of epidemiological studies. Eur Arch Psychiatry Clin Neurosci. (2024) 274:114. doi: 10.1007/s00406-024-01764-5

  • 31

    R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, Vienna, Austria (2013). Available online at: http://www.R-project.org/ (Accessed December 1, 2023).

  • 32

    HarrisRJDeeksJJAltmanDGBradburnMJHarbordRMSterneJAC. Metan: fixed- and random-effects meta-analysis. Stata J. (2008) 8:328. doi: 10.1177/1536867x0800800102

  • 33

    HigginsJPTThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557

  • 34

    The World Bank Group.Countries and Economies. (2023). https://data.worldbank.org (Accessed December 5, 2023).

  • 35

    OkuboNMatsuzakaMTakahashiISawadaKSatoSAkimotoNet al. Relationship between self-reported sleep quality and metabolic syndrome in general population. BMC Public Health. (2014) 14:562. doi: 10.1186/1471-2458-14-562

  • 36

    HinzAGlaesmerHBrählerELöfflerMEngelCEnzenbachCet al. Sleep quality in the general population: psychometric properties of the Pittsburgh Sleep Quality Index, derived from a German community sample of 9284 people. Sleep Med. (2017) 30:5763. doi: 10.1016/j.sleep.2016.03.008

  • 37

    Madrid-ValeroJJMartínez-SelvaJMCoutoBSánchez-RomeraJFOrdoñanaJR. Age and gender effects on the prevalence of poor sleep quality in the adult population. Gaceta Sanitaria. (2017) 31:1822. doi: 10.1016/j.gaceta.2016.05.013

  • 38

    VisvalingamNSathishTSoljakMChuaAPDunleavyGDivakarUet al. Prevalence of and factors associated with poor sleep quality and short sleep in a working population in Singapore. Sleep Health. (2020) 6:277–87. doi: 10.1016/j.sleh.2019.10.008

  • 39

    LuLWangSBRaoWZhangQUngvariGSNgCHet al. The prevalence of sleep disturbances and sleep quality in older chinese adults: A comprehensive meta-analysis. Behav Sleep Med. (2019) 17:683–97. doi: 10.1080/15402002.2018.1469492

  • 40

    JahramiHDewald-KaufmannJFarisM-IAlAnsariAMSTahaMAlAnsariN. Prevalence of sleep problems among medical students: a systematic review and meta-analysis. J Public Health. (2020) 28:605–22. doi: 10.1007/s10389-019-01064-6

  • 41

    GuHKongWYinHZhengY. Prevalence of sleep impairment in patients with tinnitus: a systematic review and single-arm meta-analysis. Eur Arch Oto-Rhino-Laryngol. (2022) 279:2211–21. doi: 10.1007/s00405-021-07092-x

  • 42

    WangBDuanRDuanL. Prevalence of sleep disorder in irritable bowel syndrome: A systematic review with meta-analysis. Saudi J Gastroenterol. (2018) 24:141–50. doi: 10.4103/sjg.SJG_603_17

  • 43

    HöglBEGómez-ArévaloGGarcíaSScipioniORubioMBlancoMet al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson’s disease. Neurology. (1998) 50:1332–9. doi: 10.1212/wnl.50.5.1332

  • 44

    SchützLSixel-DöringFHermannW. Management of sleep disturbances in parkinson’s disease. J Parkinson’s Dis. (2022) 12:2029–58. doi: 10.3233/JPD-212749

  • 45

    SunYLaksonoISelvanathanJSaripellaANagappaMPhamCet al. Prevalence of sleep disturbances in patients with chronic non-cancer pain: A systematic review and meta-analysis. Sleep Med Rev. (2021) 57:101467. doi: 10.1016/j.smrv.2021.101467

  • 46

    MirghaedMTSepehrianRRakhshanAGorjiH. Sleep quality in Iranian hemodialysis patients: A systematic review and meta-analysis. Iran J Nurs Midwifery Res. (2019) 24:403–9. doi: 10.4103/ijnmr.IJNMR_184_18

  • 47

    ZengLNYangYWangCLiXHXiangYFHallBJet al. Prevalence of poor sleep quality in nursing staff: A meta-analysis of observational studies. Behav Sleep Med. (2020) 18:746–59. doi: 10.1080/15402002.2019.1677233

  • 48

    VidottiVRibeiroRPGaldinoMJQMartinsJT. Burnout Syndrome and shift work among the nursing staff. Rev Latino-Americana Enfermagem. (2018) 26:e3022. doi: 10.1590/1518-8345.2550.3022

  • 49

    LixLMHobsonDEAzimaeeMLeslieWDBurchillCHobsonS. Socioeconomic variations in the prevalence and incidence of Parkinson’s disease: a population-based analysis. J Epidemiol Community Health. (2010) 64:335–40. doi: 10.1136/jech.2008.084954

  • 50

    PeralesFPlageS. Losing ground, losing sleep: Local economic conditions, economic vulnerability, and sleep. Soc Sci Res. (2017) 62:189203. doi: 10.1016/j.ssresearch.2016.08.006

  • 51

    JourdainVASchechtmannG. Health economics and surgical treatment for parkinson’s disease in a world perspective: results from an international survey. Stereotactic Funct Neurosurg. (2014) 92:71–9. doi: 10.1159/000355215

  • 52

    OguhOVidenovicA. Inpatient management of parkinson disease: current challenges and future directions. Neurohospitalist. (2012) 2:2835. doi: 10.1177/1941874411427734

  • 53

    MerlinoGGigliGL. Sleep-related movement disorders. Neurol Sci. (2012) 33:491513. doi: 10.1007/s10072-011-0905-9

  • 54

    De CockVCVidailhetMArnulfI. Sleep disturbances in patients with parkinsonism. Nat Clin Pract Neurol. (2008) 4:254–66. doi: 10.1038/ncpneuro0775

  • 55

    DobingSFrolovaNMcAlisterFRingroseJ. Sleep quality and factors influencing self-reported sleep duration and quality in the general internal medicine inpatient population. PloS One. (2016) 11:e0156735. doi: 10.1371/journal.pone.0156735

  • 56

    ParsapourKKonAADharmarMMcCarthyAKYangHHSmithACet al. Connecting hospitalized patients with their families: case series and commentary. Int J Telemed Appl. (2011) 2011:804254. doi: 10.1155/2011/804254

  • 57

    LihuaY. National symposium on extrapyramidal diseases held in Shanghai. Shanghai Med. (1985) 02):105.

  • 58

    PostumaRBBergD. The New Diagnostic Criteria for Parkinson's Disease. Int Rev Neurobiol. (2017). 132:5578. doi: 10.1016/bs.irn.2017.01.008

  • 59

    LiuMLuoYJGuHYWangYMLiuMHLiKet al. Sex and onset-age-related features of excessive daytime sleepiness and night-time sleep in patients with Parkinson’s disease. BMC Neurol. (2021) 21:165. doi: 10.1186/s12883-021-02192-x

  • 60

    HuTOuRLiuHHouYWeiQSongWet al. Gender and onset age related-differences of non-motor symptoms and quality of life in drug-naïve Parkinson’s disease. Clin Neurol Neurosurg. (2018) 175:124–9. doi: 10.1016/j.clineuro.2018.11.001

  • 61

    KägiGKleinCWoodNWSchneiderSAPramstallerPPTadicVet al. Nonmotor symptoms in Parkin gene-related parkinsonism. Movement Disord. (2010) 25:1279–84. doi: 10.1002/mds.22897

  • 62

    GuoXSongWChenKChenXZhengZCaoBet al. Gender and onset age-related features of non-motor symptoms of patients with Parkinson’s disease – A study from Southwest China. Parkinsonism Related Disord. (2013) 19:961–5. doi: 10.1016/j.parkreldis.2013.06.009

  • 63

    BraakHTrediciKDRübUde VosRAIJansen SteurENHBraakE. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. (2003) 24:197211. doi: 10.1016/S0197-4580(02)00065-9

  • 64

    GrinbergLTRuebUATdLAHeinsenH. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci. (2010) 289:81–8. doi: 10.1016/j.jns.2009.08.021

  • 65

    FerrerILópez-GonzalezICarmonaMDalfóEPujolAMartínezA. Neurochemistry and the non-motor aspects of PD. Neurobiol Dis. (2012) 46:508–26. doi: 10.1016/j.nbd.2011.10.019

  • 66

    BlesaJFoffaniGDehayBBezardEObesoJA. Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?Nat Rev Neurosci. (2022) 23:115–28. doi: 10.1038/s41583-021-00542-9

  • 67

    ChenPZhangLShaSLamMILokKIChowIHIet al. Prevalence of insomnia and its association with quality of life among Macau residents shortly after the summer 2022 COVID-19 outbreak: A network analysis perspective. Original Research. Front Psychiatry. (2023) 14:1113122. doi: 10.3389/fpsyt.2023.1113122

  • 68

    AustinKWAmeringerSWCloudLJ. An integrated review of psychological stress in parkinson’s disease: biological mechanisms and symptom and health outcomes. Parkinson’s Dis. (2016) 2016:9869712. doi: 10.1155/2016/9869712

  • 69

    DissanayakaNNSellbachAMathesonSO'SullivanJDSilburnPAByrneGJet al. Anxiety disorders in Parkinson’s disease: Prevalence and risk factors. Movement Disord. (2010) 25:838–45. doi: 10.1002/mds.22833

  • 70

    SchragA. Quality of life and depression in Parkinson’s disease. J Neurol Sci. (2006) 248:151–7. doi: 10.1016/j.jns.2006.05.030

  • 71

    LegerD. Sleep and Quality of Life in Insomnia, In: Sleep and Quality of Life in Clinical Medicine, VersterJCPandi-PerumalSRStreinerDL, Editors. (2008) Totowa, NJ: Humana Press p. 4751.

  • 72

    MaquetP. The role of sleep in learning and memory. Science. (2001) 294:1048–52. doi: 10.1126/science.1062856

  • 73

    HobsonJAPace-SchottEF. The cognitive neuroscience of sleep: neuronal systems, consciousness and learning. Nat Rev Neurosci. (2002) 3:679–93. doi: 10.1038/nrn915

  • 74

    BrownCAKuoMPhillipsLBerryRTanM. Non-pharmacological sleep interventions for youth with chronic health conditions: A critical review of the methodological quality of the evidence. Disability Rehabilitation. (2013) 35:1221–55. doi: 10.3109/09638288.2012.723788

  • 75

    HenrichJHeineSJNorenzayanA. The weirdest people in the world?Behav Brain Sci. (2010) 33:6183. doi: 10.1017/S0140525X0999152X

  • 76

    MaHRenY. Correlation analysis of sleep disorder and cognitive dysfunction in patients with Parkinson disease. Chin J Clinicians(Electronic Ed). (2015) 9:3945. doi: 10.3877/cma.j.issn.1674-0785.2015.23.011

  • 77

    ChenJZhangQZhouSYangJFengY. Analysis of sleep disorders in patients with Parkinson’s disease. Zhejiang Med. (2013) 35:1275–7.

  • 78

    ChenQHuGHanYZhangHZhangY. Clinical study on non-motor symptoms of Parkinson’s disease. Chin J Gerontol. (2008) 28:1829–30. doi: 10.3969/j.issn.1005-9202.2008.18.028

  • 79

    ChenZHongXChenZH. Corrlation between sleep disturbance and motor, non-motor symptoms in patients with parkinson’s disease. J Clin Res. (2018) 35:445448,452. doi: 10.3969/j.issn.1671-7171.2018.03.009

  • 80

    GuoPYuSZuoLLiuLPuYHuYet al. The clinical features, related factors and the changes of video polysomnography in patients with Parkinson disease accompanied with sleep disorders. Chin J Neuroimmunol Neurol. (2018) 25:2631.

  • 81

    GuoJ. Analysis and nursing care of factors related to sleep disorders in patients with Parkinson’s disease. Chin J Pratical Nervous Dis. (2014) 17:139–40.

  • 82

    YuanDHuJZhaoQWangXZhangXLiJF. Correlation between progression of Parkinson disease and depression and sleep disorders. J China Med Univ. (2020) 49:326–30. doi: 10.12007/j.issn.0258-4646.2020.04.008

  • 83

    XueD. Investigation on the current status of sleep disorders in patients with Parkinson’s disease and nursing methods. Electronic J Pract Clin Nurs Sci. (2019) 4:103,105.

  • 84

    HuXZhangB. Clinical analysis of sleep disorders in patients with Parkinson’s disease. J Int Neurol Neurosurg. (2009) 36:201–5. doi: 10.16636/j.cnki.jinn.2009.03.013

  • 85

    ChengLYuJWuD. Analysis on related factors of the sleep disorder to patients with Parkinson disease. Chin J Pratical Nervous Dis. (2013) 16:17–8.

  • 86

    WangXFengTGuZLiuPChenB. Assessment of sleep disturbance based on the clinical heterogeneity of early-stage idiopathic Parkinson’s disease. Clin Med China. (2015) 2):103–6. doi: 10.3760/cma.j.issn.1008-6315.2015.02.003

  • 87

    WangXFengTGuZLiuPZhangXChenB. Relationship between sleep disturbance and non-motor symptoms in Parkinson’s disease patients. Chin J Geriatric Heart Brain Vessel Dis. (2015) 17:507–10. doi: 10.3969/j.issn.1009-0126.2015.05.019

  • 88

    WangHWangY. Eletroencephalogram changes of patients with parkinson’s disease, sleep disorder and cognition hypofuntion. Syst Med. (2018) 3:20–2. doi: 10.19368/j.cnki.2096-1782.2018.11.020

  • 89

    WangZSunWMaJShiXLiMHuangSet al. The analysis of the relationship between sleep disorders and mental symptoms in patients with Parkinson disease. Chin J Nerv Ment Dis. (2021) 47:7882. doi: 10.3969/j.issn.1002-0152.2021.02.003

  • 90

    MaoJZhangM. Effects of sleep quality on prospective memory and neuropsychological related indicators in patients with Parkinson’s disease. Zhejiang Clin Med J. (2020) 22:259260,265.

  • 91

    MaoCDaiYLiuC. Analysis of sleep disorder in patients with early parkinson’s disease. Jiangsu Med J. (2007) 33:897–9. doi: 10.3969/j.issn.0253-3685.2007.09.013

  • 92

    MaoYSaimaitiY. Clinical observation of non-motor symptoms in patients with Parkinson’s disease. Med Inf Chin. (2014) 20):124–5. doi: 10.3969/j.issn.1006-1959.2014.20.136

  • 93

    LiangPCuiLWuZYuJChenM. A survey of’Sleep related cognitions in pafients with pakinson”s disease and related nursing. Clin Med Engineering. (2015) 22:928–9. doi: 10.3969/j.issn.1674—4659.2015.07.0928

  • 94

    ZhuYZhengHYangQ. Incidence and related factors of psychosis in parkinson disease. Chin J Med Guide. (2011) 13:1682–3. doi: 10.3969/j.issn.1009-0959.2011.10.017

  • 95

    CaoWLiuXMaCChenYRenXZhangHet al. Study on related factors of non ⁃ motor symptoms in patients with different motor phenotypes of Parkinson’s disease. J Nanjing Med University(Natural Sci). (2019) 39:1764–8. doi: 10.7655/NYDXBNS20191213

  • 96

    CaoSYuDSuRGuoY. Analysis of the incidence of sleep disorders and related influencing factors in patients with Parkinson’s disease. Chin J Integr Med On Cardio-/Cerebrovascuiar Dis. (2019) 17:1257–9. doi: 10.12102/j.issn.1672-1349.2019.08.041

  • 97

    ZhangJGaoPWeiJ. Investigation on the current status of sleep disorders in patients with Parkinson’s disease and nursing strategies. Chin Community Physician (Med Professional). (2010) 12:175–6.

  • 98

    ZhangHZhangLZhuJJiangXWuZ. Analysis of the incidence and clinical features of sleep disorders in patients with Parkinson’s disease. Pract Geritr. (2020) 34:674–8. doi: 10.3969/j.issn.1003-9198.2020.07.011

  • 99

    ZhangYLiuYWangWLiuHGuP. Influential factors of autonomic nervous dysfunction in patients with Parkinson’s disease. J Clin Internal Med. (2022) 39:386–90. doi: 10.3969/j.issn.1001-9057.2022.06.008

  • 100

    ZhangYLuoCLiaoC. Clinical analysis of sleep disorders and cognitive impairment in Parkinson’s disease. Front Med (Chinese). (2021) 11:96–7.

  • 101

    CuiWQingSLiuLChenQ. Clinical characteristics and prognosis of cognitive impairment in patients with Parkin⁃ son’s disease. J Guangxi Med Univ. (2019) 36:1923–6. doi: 10.16190/j.cnki.45-1211/r.2019.12.010

  • 102

    SongYZhaoZLiYYinQ. Influence factors and nursing of sleep disorder parkinson’s disease. Chin Foreign Med Res. (2015) 13:95–7. doi: 10.14033/j.cnki.cfmr.2015.23.050

  • 103

    SongJSunXMaLLuLFanKWangZet al. Analysis of cognitive impairment and its related factors in Parkinson’s disease. Chin J Gerontol. (2019) 39:858–62. doi: 10.3969/j.issn.1005-9202.2019.04.031

  • 104

    SunLGaoXMoDGongD. Clinical study on sleep disorders and related factors in patients with Parkinson’s disease. Nerve Injury Funct Reconstruction. (2015) 2):159–61. doi: 10.3870/sjsscj.2015.02.021

  • 105

    LuY. Investigation on the current status of sleep disorders in patients with Parkinson’s disease and research on nursing strategies. Shanxi Med J. (2019) 48:388–90. doi: 10.3969/j.issn.0253-9926.2019.03.050

  • 106

    LiuHChenK. Relationship study between Glu and GABA and sleep disorders in patients with Parkinson’s disease. Proceeding Clin Med. (2018) 27:27–9. doi: 10.16047/j.cnki.cn14-1300/r.2018.01.008

  • 107

    LiuYLiJFangQQinYWeiY. Study of health related quality of life in patients with Parkinson’s disease. World Latest Med Inform. (2013) 16):5859,31. doi: 10.3969/j.issn.1671-3141.2013.16.031

  • 108

    LiuHChouFMaLZhangYWangMGuP. Effect of sleep quality on cognitive function in mild-o-moderate Parkinson patients. J Neurosci Ment Health. (2014) 14:502–5. doi: 10.3969/j.issn.1009-6574.2014.05.021

  • 109

    LiuDWangYWangQMaoHWangS. Study on the correlation between discharge readiness, family resilience and alexithymia in patients with Parkinson’s disease. Chin Gen Pract Nursing. (2022) 20:4723–6. doi: 10.12104/j.issn.1674-4748.2022.33.029

  • 110

    YuLPengLLuoTHuangCWangZ. Relationship study between sleep disorders and EEG activity, neuropsychological indicators and health-related quality of life in patients with parkinson’s disease. Prog Modern Biomed. (2022) 22:3863–7. doi: 10.13241/j.cnki.pmb.2022.20.012

  • 111

    YiQChenY-PLiJ-TLiJ-YQiuQ-XWangD-Let al. Worse sleep quality aggravates the motor and non-motor symptoms in parkinson’s disease. Article. Front Aging Neurosci. (2022) 14:887094. doi: 10.3389/fnagi.2022.887094

  • 112

    WangJXiongKChaoJZhuangSLiJLiuC. Seasonal variations of nonmotor symptoms in patients with Parkinson’s disease in Southeast China. Article in Press. Chin Med J. (2022). doi: 10.1097/CM9.0000000000002276

  • 113

    TangXYangJZhuYGongHSunHChenFet al. High PSQI score is associated with the development of dyskinesia in Parkinson’s disease. Article. NPJ Parkinson’s Dis. (2022) 8:124. doi: 10.1038/s41531-022-00391-y

  • 114

    SongYGuZAnJChanP. Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson’s disease. Neurol Sci. (2014) 35:1991–6. doi: 10.1007/s10072-014-1879-1

  • 115

    ShulmanLMTabackRLBeanJWeinerWJ. Comorbity of the nonmotor symptoms of Parkinson’s disease. Article. Movement Disord. (2001) 16:507–10. doi: 10.1002/mds.1099

  • 116

    SahebzadehNFarsi BafMMHomamSM. Sleep quality and cognitive impairment in patients with Parkinson’s disease in Iran. Article. Turk Norol Dergisi. (2016) 22:121–6. doi: 10.4274/tnd.84755

  • 117

    QiuFGuPLiuWLiD. The spectrum characteristics of Parkinson’s disease (PD) patients with sleep disorders. Neurol Sci. (2022) 43:327–33. doi: 10.1007/s10072-021-05240-z

  • 118

    QinXLiXChenGChenXShiMLiuXKet al. Clinical features and correlates of poor nighttime sleepiness in patients with parkinson’s disease. Parkinsons Dis. (2020) 2020:6378673. doi: 10.1155/2020/6378673

  • 119

    MahaleRYadavRPalPK. Quality of sleep in young onset Parkinson’s disease: Any difference from older onset Parkinson’s disease. Parkinsonism Relat Disord. (2015) 21:461–4. doi: 10.1016/j.parkreldis.2015.02.007

  • 120

    LouterMvan der MarckMAPevernagieDAAMunnekeMBloemBROvereemS. Sleep matters in Parkinson’s disease: Use of a priority list to assess the presence of sleep disturbances. Article. Eur J Neurol. (2013) 20:259–65. doi: 10.1111/j.1468-1331.2012.03836.x

  • 121

    LinYYChenRSLuCSHuangYZWengYHYehTHet al. Sleep disturbances in Taiwanese patients with Parkinson’s disease. Brain Behav. (2017) 7:e00806. doi: 10.1002/brb3.806

  • 122

    HavlikovaEvan DijkJPNagyovaIRosenbergerJMiddelBDubayovaTet al. The impact of sleep and mood disorders on quality of life in Parkinson’s disease patients. J Neurol. (2011) 258:2222–9. doi: 10.1007/s00415-011-6098-6

  • 123

    GaoLHuangWCaiLLiH. Association between sleep disturbances and pain subtypes in Parkinson’s disease. Neurol Sci. (2022) 43:4785–90. doi: 10.1007/s10072-022-06030-x

  • 124

    DuncanGWKhooTKYarnallAJO'BrienJTColemanSYBrooksDJet al. Health-related quality of life in early Parkinson’s disease: The impact of nonmotor symptoms. Movement Disord. (2014) 29:195202. doi: 10.1002/mds.25664

  • 125

    DingMZhuYLuZShenHDaiJZhuX. Analysis of independent risk factors affecting cognitive function in patients with Parkinson’s disease. Chin J Pract Nervous Dis. (2020) 23:1590–5. doi: 10.12083/sysj.2020.17.006

  • 126

    ShafazandSWallaceDMArheartKLVargasSLucaCCMooreHet al. Insomnia, sleep quality, and quality of life in mild to moderate parkinson’s disease. Ann Am Thorac Soc. (2017) 14:412–9. doi: 10.1513/AnnalsATS.201608-625OC

  • 127

    SkorvanekMNagyovaIRosenbergerJKrokavcovaMGhorbani SaeedianRGroothoffJWet al. Clinical determinants of primary and secondary fatigue in patients with Parkinson’s disease. J Neurol. (2013) 260:1554–61. doi: 10.1007/s00415-012-6828-4

  • 128

    ShiFGuanHGaoZHuangYWangD. Clinical characteristics of parkinson’S disease patients with sleep disorder and effect of anti resistance exercise intervention. J Int Psychiatry. (2023) 50:799801,805. doi: 10.13479/j.cnki.jip.2023.04.011

  • 129

    DongRTanH. Correlation of sleep disorders with emotional apathy and executive function in Parkinson disease. J Apoplexy Nervous Dis. (2023) 40:807–12. doi: 10.19845/j.cnki.zfysjjbzz.2023.0180

  • 130

    ChangCWFanJYChangBLWuYR. Anxiety and levodopa equivalent daily dose are potential predictors of sleep quality in patients with parkinson disease in Taiwan. Front Neurol. (2019) 10:340. doi: 10.3389/fneur.2019.00340

  • 131

    ShiY. Incidence of sleep disturbances in patients with Parkinson’s disease and its relationship to negative Emotions and qualiy of life. J Int Psychiatry. (2023) 50:796–8. doi: 10.13479/j.cnki.jip.2023.04.009

  • 132

    LiHYuanXYeQYuanCGaoCHuY. Analysis of factors influencing sleep disorders and the distribution characteristics of traditional Chinese medicine syndromes in people with early⁃or mid⁃stage Parkinson’s disease. Shanghai J Tradit Chin Med. (2023) 57:21–5. doi: 10.16305/j.1007-1334.2023.2208083

  • 133

    GuiXWangLWuCSunX. Characteristics of sleep disturbances in Parkinson’ s disease patients with young onset and late onset. Zhejiang Med. (2018) 40:1698–701. doi: 10.12056/j.issn.1006-2785.2018.40.15.2017-3203

  • 134

    HuYSunYLanZWangHLiXZhongY. Analysis of the relationships betwen changes in polysomnographic EEG map features and cogni- tive dysfunction in patients with Parkinson’s disease. Chin J Stereotact Funct Neurosurg. (2023) 36:7681. doi: 10.19854/j.cnki.1008-2425.2023.02.0003

  • 135

    NiuXGouY. Analysis of related influential factors for sleep disorder in patients with Parkinson’s disease. Nao Yu Shen Jing Ji Bing Za Zhi. (2015) 23:353–8.

Summary

Keywords

Parkinson’s disease, sleep quality, meta-analysis, prevalence, epidemiology

Citation

Si TL, Wang Y-Y, Li J-X, Bai W, Sun H-L, Rao S-Y, Zhu H-Y, Ungvari GS, Su Z, Cheung T, Ng CH, Xiang Y-T and Wang G (2025) Poor sleep quality among patients with Parkinson’s disease: a meta-analysis and systematic review. Front. Psychiatry 16:1606743. doi: 10.3389/fpsyt.2025.1606743

Received

16 May 2025

Accepted

26 June 2025

Published

16 July 2025

Volume

16 - 2025

Edited by

Luigi De Gennaro, Sapienza University of Rome, Italy

Reviewed by

Caterina Leitner, Vita-Salute San Raffaele University, Italy

Loida Camargo, University of Cartagena, Colombia

Updates

Copyright

*Correspondence: Chee H. Ng, ; Yu-Tao Xiang, ; Gang Wang,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics